Cell surface receptor expression patterns in osteosarcoma

被引:83
作者
Hassan, Sheref E. [1 ,2 ]
Bekarev, Mikhail
Kim, Mimi Y. [4 ]
Lin, Juan [4 ]
Piperdi, Sajida [2 ,3 ]
Gorlick, Richard [2 ,3 ]
Geller, David S. [1 ,2 ]
机构
[1] Montefiore Med Ctr, Dept Orthopaed Surg, Bronx, NY 10467 USA
[2] Childrens Hosp Montefiore, Bronx, NY USA
[3] Montefiore Med Ctr, Dept Pediat, Bronx, NY 10467 USA
[4] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA
关键词
osteosarcoma; surface receptors; targeted therapy; flow cytometry; IGF-2R; GROWTH-FACTOR RECEPTOR; PHASE-II; IMATINIB MESYLATE; BREAST-CANCER; SOLID TUMORS; THERAPY; METASTASIS; SURVIVAL; PROGRAM; SARCOMA;
D O I
10.1002/cncr.26339
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Although the presence of numerous cell signaling receptors in osteosarcoma is known, their simultaneous characterization has not been performed to date. The current study sought to characterize and quantify the expression of cell surface receptors across a variety of osteosarcoma cell lines. METHODS: Standard (n=4) and patient-derived (n=10) osteosarcoma cell lines were cultured and labeled with antibodies to epidermal growth factor receptor, human epidermal growth factor receptor (HER)-2, HER-3, HER-4, insulin-like growth factor 1 receptor (IGF-1R), IGF-2R, insulin receptor (IR), vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, c-Met, fibroblast growth factor receptor (FGFR)-2, FGFR-3, and platelet-derived growth factor receptor (PDGFR)-b. Cell surface examination was performed using flow cytometry, and the geometric fluorescent mean for each receptor was calculated and compared against a positive control. RESULTS: Significant overexpression of IGF-2R was shown in all cell lines, with an average geometric mean above the upper expression quartile. A variable expression pattern was seen for c-Met, PDGFR-b, IR, IGFR-1, HER-2, and VEGFR-3 with expression values for the remaining receptors mainly in the lower quartile. An apparent association between the expression of IGF-1R and HER-2 and between the expression of PDGFR-b and IR was demonstrated. CONCLUSION: IGF-2R was consistently overexpressed on the cell surface across all tested osteosarcoma cell lines. Substantial, although variable, expression of c-Met, HER-2, IGF-1R, VEGFR-3, IR, and PDGFR-b was demonstrated as well, suggesting that these receptors may contribute to osteosarcoma aggressiveness and biological heterogeneity and may serve as potential targets within a subset of tumors. Associated receptor expression may provide new insight into common regulatory factors or pathways. Targeting either common factors or targeting multiple specific receptors may have therapeutic relevance. Cancer 2012; 118: 740-9. (C) 2011 American Cancer Society.
引用
收藏
页码:740 / 749
页数:10
相关论文
共 32 条
[1]   Correlation Between Clinical Outcome and Growth Factor Pathway Expression in Osteogenic Sarcoma [J].
Abdeen, Ayesha ;
Chou, Alexander J. ;
Healey, John H. ;
Khanna, Chand ;
Osborne, Tanasa S. ;
Hewitt, Stephen M. ;
Kim, Mimi ;
Wang, Dan ;
Moody, Karen ;
Gorlick, Richard .
CANCER, 2009, 115 (22) :5243-5250
[2]   Emerging Targeted Therapies for Breast Cancerd [J].
Alvarez, Ricardo H. ;
Valero, Vicente ;
Hortobagyi, Gabriel N. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) :3366-3379
[3]   Insulin Receptor Isoform A and Insulin-like Growth Factor II as Additional Treatment Targets in Human Osteosarcoma [J].
Avnet, Sofia ;
Sciacca, Laura ;
Salerno, Manuela ;
Gancitano, Giovanni ;
Cassarino, Maria Francesca ;
Longhi, Alessandra ;
Zakikhani, Mahvash ;
Carboni, Joan M. ;
Gottardis, Marco ;
Giuti, Armando ;
Pollak, Michael ;
Vigneri, Riccardo ;
Baldini, Nicola .
CANCER RESEARCH, 2009, 69 (06) :2443-2452
[4]   A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A children's oncology group study [J].
Bond, Mason ;
Bernstein, Mark L. ;
Pappo, Alberto ;
Schultz, Kirk R. ;
Krailo, Mark ;
Blaney, Susan M. ;
Adamson, Peter C. .
PEDIATRIC BLOOD & CANCER, 2008, 50 (02) :254-258
[5]   Phase II Study to Evaluate the Efficacy and Safety of Neoadjuvant Lapatinib Plus Paclitaxel in Patients With Inflammatory Breast Cancer [J].
Boussen, Hamouda ;
Cristofanilli, Massimo ;
Zaks, Tal ;
DeSilvio, Michelle ;
Salazar, Vanessa ;
Spector, Neil .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) :3248-3255
[6]   Targeting the IGF1 axis in cancer proliferation [J].
Bruchim, Ilan ;
Attias, Zohar ;
Werner, Haim .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2009, 13 (10) :1179-1192
[7]   Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signaling [J].
Cantiani, Lara ;
Manara, Maria Cristina ;
Zucchini, Cinzia ;
De Sanctis, Paola ;
Zuntini, Monia ;
Valvassori, Luisa ;
Serra, Massimo ;
Olivero, Martina ;
Di Renzo, Maria Flavia ;
Colombo, Mario Paolo ;
Picci, Piero ;
Scotlandi, Katia .
CANCER RESEARCH, 2007, 67 (16) :7675-7685
[8]  
Children's Oncology Group, 2000, CHEM TRAST TREAT PAT
[9]   Therapy for osteosarcoma: Where do we go from here? [J].
Chou A.J. ;
Geller D.S. ;
Gorlick R. .
Pediatric Drugs, 2008, 10 (5) :315-327
[10]   Phase II Multicenter Trial of Imatinib in 10 Histologic Subtypes of Sarcoma Using a Bayesian Hierarchical Statistical Model [J].
Chugh, Rashmi ;
Wathen, J. Kyle ;
Maki, Robert G. ;
Benjamin, Robert S. ;
Patel, Shreyaskumar R. ;
Myers, Paul A. ;
Priebat, Dennis A. ;
Reinke, Denise K. ;
Thomas, Dafydd G. ;
Keohan, Mary L. ;
Samuels, Brian L. ;
Baker, Laurence H. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) :3148-3153